Browsing by Author "Abdur Rauf"

Now showing 1 - 2 of 2

Green Synthesis of Iron Oxide NPs (IONPs) by Using Aqueous Extract of Parthenium hysterophorus Linnaeus for the In-vitro Antidiabetic and Anti-inflammatory Activities
(2024-11-13) Abdur Rauf; Ahmad, Zubair; Raisham; Ibrahim, Muhammad; Rezaul Islam, Md.; A. Hemeg, Hassan; S. Al-Awthan, Yahya; Bahattab, Omar; Abdur Rahman; Umar, Muhammad; Muhammad, Naveed
The Parthenium hysterophorus Linnaeus is one of the anti-inflammatory and antidiabetic ethnomedicine. Therefore the formulation of this plant as nanoparticles will be fruitful anti-inflammatory and antidiabetic as compared to conventional extract. In the current study, the aqueous kernel extract from Parthenium hysterophorus Linnaeus was subjected to synthesize iron oxide nanoparticles (IONPs) and explored their anti-inflammatory and anti-diabetic potentials. The results indicate that the aqueous kernel extract effectively produced IONPs, which were verified using standard analytical methods. UV-visible spectrophotometer analysis was used to check the formation of IONPs. The Fourier-transform infrared spectroscopy (FTIR) was used to check numerous functional groups from the valuable phytochemicals present in the extract. These functional groups play crucial roles as reducing, capping, and stabilizing agents during the synthesis of IONPs. Additionally, scanning electron microscopy (SEM) were utilized to investigate the surface characteristics of the nanoparticles. Notably, the IONPs fabricated from the extract demonstrated promising anti-inflammatory activity, inhibiting Human RBC by 79% and Heat Induced Hemolysis by 72%, as well as showing anti-diabetic potential with 60% inhibition of yeast glucose uptake and 72% inhibition of α-amylase activity, all at a concentration of 100 μg mL-1. These effects were partly comparable to standard drugs with anti-inflammatory activity of 85% inhibition of Human RBC and 78% inhibition of Heat Induced Hemolysis, and anti-diabetic activity of 67% inhibition of yeast glucose uptake and 78% inhibition of alpha amylase.
Molecular insights into withaferin A: A holistic approach to cancer therapy
(2024-12-15) Rezaul Islam, Md.; Abdur Rauf; Rakesh, M. Meenakshi; Akash, Shopnil; Fakir, M. Naeem Hossain; Islam, Samiul; Naba, Afifa Farzana; Al-Imran, Md. Ibrahim Khalil; AlOmar, Taghrid S.; Ogaly, Hanan A.; Alzahrani, Hayat E.; Thiruvengadam, Rekha; Thiruvengadam, Muthu
Withaferin A (WA), a significant phytoconstituent of Withania somnifera, belongs to the triterpenoid class of C28-steroidal lactones found in nature. It has been utilized in traditional and native medical systems to treat various diseases such as cancers. It also has pro-apoptotic, anti-inflammatory, metabolic, and anticancer properties. In addition, it interacts with NF-κB, STAT, Hsp90, ER, and p53, thereby suppressing cancer cell growth and reducing the cell cycle at the G2/M stage. This review discusses the pro-apoptotic properties of WA, such as the generation of ROS, activation of PAR-4, development of ER stress, and activation of p53. This provides a comprehensive analysis of the molecular mechanisms of WA, highlighting its intricate effects on cancer cell signaling pathways, apoptosis, and tumor microenvironment (TME) regulation. Moreover, the ability to modify the TME through immune response modulation underscores its importance in comprehensive cancer treatment. The involvement of WA in oncogenic pathways that lead to malignant neoplasms and its potential therapeutic effects when combined with other cancer treatments are promising. This review indicates that WA's strong pharmacological profile, especially in combating cancer, could be advantageous for developing new cancer therapy medications. Furthermore, it emphasizes the potential of WA as a supplement to standard medications and encourages further clinical trials to assess its efficacy and safety in various cancer types. Moreover, it indicates a growing understanding of natural chemicals in cancer therapy, which can be integrated into various treatment methods.